story of the week
Longer-Interval Dosing of Zoledronic Acid Effective in Patients With Bone Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
JAMA 2017 Jan 03;317(1)48-58, AL Himelstein, JC Foster, JL Khatcheressian, JD Roberts, DK Seisler, PJ Novotny, R Qin, RS Go, SS Grubbs, T O'Connor, MR Velasco, D Weckstein, A O'Mara, CL Loprinzi, CL ShapiroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.